Style Editor Docs
     
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • Research (White Papers)
    • US FDA IDE Application
      • US FDA IDE Pre-Submission Process
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Therapy Pets
    • Veterinarians
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About Us
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Vivos Inc.
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
   Contact Us
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • Research (White Papers)
    • US FDA IDE Application
      • US FDA IDE Pre-Submission Process
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Therapy Pets
    • Veterinarians
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About Us
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Vivos Inc.
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
  1. IsoPet®

IsoPet®

RadioGel™ | Yttrium-90 (Y-90) Precision Radionuclide Therapy (PRnT) for Veterinary Applications

Our IsoPet® division is focused on bringing RadioGel™ yttrium-90 Precision Radionuclide Therapy to veterinary oncologists to treat dogs, cats and horses suffering from cancerous tumors.



Initial treatments were coordinated through the Chair of the company’s Veterinary Medicine Advisory Board, Dr. Alice Villalobos. There are over 150 million pet dogs and cats, with over 1/3 of the households in the US owning at least one dog, and just under 1/3 owning at least one cat.




Dr. Alice Villalobos stated: "I am quite excited at the opportunity to work with RadioGel's™ team to integrate their products into the cancer treatments of companion animals. Cancer affects 50% of dogs over age ten and one in four dogs under age ten. For many years, we have been searching for a useable and effective agent such as IsoPet® (RadioGel™ 90-Y) brachytherapy devices that can be delivered into tumors on an outpatient basis. I believe that veterinary oncologists around the globe will finally have an ideal product line for the treatment of accessible and inoperable tumors."



Our IsoPet® division is establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance. The division will also provide product awareness and education to veterinary oncologists.

 


CEO | President Mike Korenko stated: “IsoPet® allows specific resources to focus on the use of our RadioGel™ yttrium-90 brachytherapy products in the veterinary space. We believe that IsoPet® is positioned to build a significant presence in the cancer treatment tool-kit of veterinary oncologists.”

 

Learn more about IsoPet's® first companion animal treatments through a study at Washington State University funded by the Washington State Life Sciences Discovery Fund for the treatment of feline sarcoma.

IsoPet® Product Sheet – 2023

Download
IsoPet® Product Sheet - Technical Data Summary
IsoPet® Product Sheet 2023 (8.5 × 11 in)
Adobe Acrobat Document 1.2 MB
Download


IsoPet's yttrium (90-Y) Precision Radionuclide Therapy (PRnT) device can be delivered into tumors on an out patient basis. I believe that veterinary oncologists around the globe finally have an ideal product for the treatment of accessible and inoperable tumors.

Dr. Alice Villalobos – Chair Veterinary Medical Advisory Board

IsoPet® Therapy Dog/Cat Application
IsoPet® Therapy Equine Application

Vivos, Inc.

Precision Radionuclide Therapy (PRnT)

OTCQB: RDGL

contact: info@radiogel.com


Home Page Cover Image: 

 

Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.

 

Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.

RadioGel™ is a hydrogel liquid containing tiny yttrium-90 (90Y)  phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® Therapy Application(s)


Precision Radionuclide Therapy (PRnT)


Vivos Inc.
 - (OTCQB: RDGL) Investor Relations 

Contact

 

Main colors
   bg-primary
   bg-primary-light
   bg-primary-dark
   bg-secondary
   bg-secondary-dark
Template sections
   body
   top-header
   header
   content
Footer Styles
   background
   text color
   link color
   horizontal line
Buttons
   style 1
   style 2
   style 3
Other elements
  social icons
  navigation color
  subnav background
Mobile navigation
   background color
   navigation color
Template configurations
has-right-nav g-font
navigation styles
size-15 weight-400 snip-nav
content styles
form-white
footer styles
o-form color-white
Typography
Heading H1
weight-600
Heading H2
weight-600
Heading H3
weight-600
Buttons
weight-600 is-uppercase
Animations

Note:
All changes made here will be applied to your entire website.
is-switcher admin-only

RadioGel™ Logo

Precision Radionuclide Therapy (PRnT)

draggable-logo

About | Privacy Policy | Cookie Policy | Sitemap
© 2023 Vivos Inc. | RadioGel™ is a registered trademark | IsoPet® is a registered trademark
Log out | Edit
  • Regional Clinics
  • IsoPet® Therapy Pets
  • Veterinarians
  • Animal Studies
  • Our IsoPet® Mission
  • Scroll to top